Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 8, Pages 1084
Publisher
MDPI AG
Online
2019-07-31
DOI
10.3390/cancers11081084
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
- (2019) Masahiro Kobayashi et al. JOURNAL OF GASTROENTEROLOGY
- Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
- (2019) Kazuomi Ueshima et al. Cancers
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization
- (2018) Yutaka Yasui et al. HEPATOLOGY RESEARCH
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.
- (2018) Markus Peck-Radosavljevic et al. JOURNAL OF CLINICAL ONCOLOGY
- Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
- (2017) Masao Omata et al. Hepatology International
- Lenvatinib in Advanced Hepatocellular Carcinoma
- (2017) Masatoshi Kudo Liver Cancer
- Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma
- (2017) Takeshi Terashima et al. Liver Cancer
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
- (2016) Jordi Bruix et al. GASTROENTEROLOGY
- Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers
- (2016) Haruki Kimura et al. Hepatology International
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- (2016) Kenji Ikeda et al. JOURNAL OF GASTROENTEROLOGY
- Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment
- (2016) Masatoshi Kudo et al. Liver Cancer
- Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)
- (2015) Masatoshi Kudo et al. DIGESTIVE DISEASES
- Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma
- (2015) Tadaaki Arizumi et al. ONCOLOGY
- Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
- (2015) Tadaaki Arizumi et al. Liver Cancer
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization
- (2014) Sadahisa Ogasawara et al. ONCOLOGY
- JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
- (2014) Masatoshi Kudo et al. Liver Cancer
- Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions
- (2013) Andrew Burroughs et al. SEMINARS IN LIVER DISEASE
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- (2012) D S Boss et al. BRITISH JOURNAL OF CANCER
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
- (2011) K. Yamada et al. CLINICAL CANCER RESEARCH
- Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines
- (2011) Kenichi Takayasu et al. JOURNAL OF HEPATOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization
- (2008) B. Wang et al. ACTA RADIOLOGICA
- Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness
- (2008) Adriana Sergio et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-β receptor inhibitor on extravasation of nanoparticles from neovasculature
- (2008) Mitsunobu R. Kano et al. CANCER SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now